Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-07-07
Butterfly Network, Inc.
Butterfly Network sells handheld ultrasound probes, cloud software, AI-enabled workflow tools, and embedded ultrasound chip licenses for healthcare use.
ai healthcare medical devices semiconductors software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Platform upside exists, but valuation still demands proof
One chip platform can serve bedside imaging, enterprise workflow, home care, and partner licensing. The opportunity is real, but equity upside depends on higher-margin software and embedded revenue becoming repeatable before incumbents commoditize the probe.

Analysis

Thesis
Butterfly can outgrow a normal device company because one regulated ultrasound chip platform can monetize through probes, workflow software, home-care programs, and embedded licensing; the limit is that shareholder upside depends on those higher-value layers scaling before larger imaging vendors compress the hardware edge.
Last Economy Alignment
Cheaper AI should widen handheld ultrasound use, and Butterfly owns the device, permissions, and workflow hooks that matter. But it is not the core compute bottleneck, and larger imaging vendors can still pressure the hardware layer.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.0x (from 5 most recent analyses)
Reasoning
Butterfly has a credible path to grow much faster than a typical medical device company because the same chip platform can sell into bedside imaging, enterprise workflow, home care, and partner licensing. I still keep the stock in a constrained bucket because the market already prices meaningful platform optionality, so equity returns likely trail revenue growth unless the recurring software and embedded mix becomes clearly durable.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The device works and the balance sheet is serviceable, so the main risk is not technical failure. The real risk is commercial shape: Butterfly must turn compliance wins, home-care pilots, and embedded partnerships into recurring high-margin revenue before larger imaging vendors bundle away the handheld advantage; otherwise revenue can grow while the stock still disappoints because today’s valuation already assumes a platform outcome.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.36
They own a real imaging device and regulated workflow that AI cannot replace with a chatbot, so cheaper AI can help more clinicians use ultrasound. The risk is that bigger imaging vendors can match enough of the workflow and distribution to keep Butterfly from becoming the toll booth.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.06
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case